Experienced in Undifferentiated Pleomorphic Sarcoma

Norihiko Nakanishi

Matsuyama, JP 
Experienced in Undifferentiated Pleomorphic Sarcoma
Matsuyama, JP 
OverviewLocationsClinical Research

Overview

Norihiko Nakanishi practices in Matsuyama, Japan. Nakanishi is rated as an Experienced expert by MediFind in the treatment of Undifferentiated Pleomorphic Sarcoma. Their top areas of expertise are Pleurisy, Undifferentiated Pleomorphic Sarcoma, Mycobacterium Avium Complex Infections, and Allergic Bronchopulmonary Aspergillosis.

Their clinical research consists of co-authoring 11 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Undifferentiated Pleomorphic Sarcoma.

Locations

Matsuyama, Japan
Other Locations
Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
Japanese Idiopathic Interstitial Pneumonias Registry
Japanese Idiopathic Interstitial Pneumonias Registry
Enrollment Status: Active_not_recruiting
Publish Date: May 13, 2024
View 2 Less Clinical Trials

11 Total Publications

Exacerbation of Paraneoplastic Neurologic Syndrome After Immune Checkpoint Inhibitor Treatment in Advanced Small Cell Lung Cancer: A Case Report.
Exacerbation of Paraneoplastic Neurologic Syndrome After Immune Checkpoint Inhibitor Treatment in Advanced Small Cell Lung Cancer: A Case Report.
Journal: Cureus
Published: February 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Nakanishi's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile